The global biologics market is projected to reach USD 567.96 Billion in 2028 at a steady revenue CAGR of 8.4% over the forecast period, according to latest analysis by Emergen Research. Some key factors attributed to steady market revenue growth include rising demand for monoclonal antibodies, recombinant hormones/proteins, gene-based & cellular-based biologics, vaccines, and molecular therapy, etc. in the treatment of diseases including cancer, infectious diseases, immunological diseases, cardiovascular diseases, and hematological diseases, among others. Also, rising use of biologics for the treatment of autoimmune diseases, comprising various arthritis types, including ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis, is playing a crucial role in driving revenue growth of the global biologics market. Biologics function by creating an inflammation disruption, thereby resulting in a reduction in joint pain.
Additionally, the rapidly increasing burden of chronic diseases globally is fueling market growth. According to statics released by World Health Organization (WHO), the burden of chronic diseases had been estimated to increase by 57.0% from 2001 to 2020. Developing countries are expected to be highly impacted, thereby contributing to 60.0% of the global burden of chronic diseases.
Get a Free sample of the report : https://www.emergenresearch.com/request-sample/61
In September 2020, Biocon Biologics Ltd. and Mylan made an announcement about the introduction of biosimilar Semglee in the US. This biosimilar is available, both in pre-filled pen and vials, and is intended for controlling high blood pressure in adults having type 2 diabetes and pediatric patients having type 1 diabetes.
Among the source segments, mammalian segment revenue is expected to register a significantly rapid growth rate over forecast period. Expression systems deploying mammalian cells for recombinant hormones/proteins can introduce appropriate protein folding, PTM (post-translational modifications), and product assembly that are essential for overall biological activity.
Among the product type segments, vaccines segment revenue is expected to expand at a relatively faster rate over forecast period. A vaccine functions by preparing the immune system to identify and fight pathogens, either bacteria or viruses. Vaccines are beneficial in reducing preventable infectious diseases, and currently, fewer number individuals suffer from the distressing effects of pertussis and measles, among other illnesses. Presently, vaccines are witnessing spiraling demand across the globe to curb the spread of COVID-19 and resulting mortalities occurring due to the disease.
Among the application segments, the cancer segment accounted for largest revenue share in 2020. Biologics assists the immune system in quickly recognizing cancer cells in the human body, as well as attacking the malignant cells, switching on/off the signals from cancerous cells and aiding in dodging the immune system cells.
The market in Asia Pacific is expected to register fastest revenue CAGR over forecast period due to improving healthcare infrastructure, rising investments in biologics development, and better reimbursement scenario in some countries in the region.
Some major companies operating in the global market include Novo Nordisk A/S, Pfizer Inc., Amgen, Sanofi, Samsung BioLogics, Merck & Co. Inc., Celltrion, AbbVie Inc., Johnson & Johnson Services Inc., Eli Lilly & Company, F Hoffman La Roche, Addgene, Novartis AG, and GlaxoSmithKline.
Request customization of the report: https://www.emergenresearch.com/request-for-customization/61
Emergence of several startups such as ILYA Pharma, Elasmogen, Cygnal Therapeutics, TiumBio, and Entos Pharmaceuticals is also contributing significantly to market growth
Furthermore, the report provides a comprehensive overview of the Biologics market along with product portfolio and market performance. The report offers key insights into market share, supply chain analysis, demand and supply ratio, import/export details, and product and consumption patterns. To gain a better understanding, the report is further segmented into sections such as product types offered by the market, application spectrum, companies, and key geographical regions where the market has established its presence.
The report is updated with the latest economic scenario and market scope with regard to the ongoing COVID-19 pandemic. The report covers growth prospects as well as current and futuristic revenue estimations in a post COVID scenario. The report also covers changing trends and market dynamics due to the pandemic and provides an accurate impact analysis of the crisis on the overall market.
Emergen Research has segmented the global biologics on the basis of source, product type, application, and region:
Source Outlook (Revenue, USD Billion; 2018-2028)
Microbial
Mammalian
Others
Product Type Outlook (Revenue, USD Billion; 2018-2028)
Monoclonal Antibodies
Vaccines
Recombinant Hormones/Proteins
Cellular-Based Biologics
Gene-Based Biologics
Others
Application Outlook (Revenue, USD Billion; 2018-2028)
Cancer
Infectious Diseases
Immunological Diseases
Cardiovascular Diseases
Hematological Disorders
Others
Key Questions Answered in the Report:
What is the growth rate of the Biologics market? What is the anticipated market valuation of Biologics industry by 2027?
What are the key growth driving and restraining factors of the Biologics market?
Who are the prominent players operating in the market? What are the key strategies adopted by these companies?
What are the key opportunities and growth prospects of the Biologics industry over the forecast period?
Which region is expected to show significant growth in the coming years?
Market Taxonomy:
Chapter 1: Methodology & Scope
Definition and forecast parameters
Methodology and forecast parameters
Data Sources
Chapter 2:
Executive Summary
Business trends
Regional trends
Product trends
End-use trends
Chapter 3:
Industry Insights
Industry segmentation
Industry landscape
Vendor matrix
Technological and innovation landscape
Chapter 4:
Regional Landscape
Chapter 5:
Company Profile
Business Overview
Financial Data
Product Landscape
Strategic Outlook
Global Biologics Market Geographical Landscape – Synopsis:
The report closely studies the growth trajectory of the global Biologics market. It brings to light the global dominance of the leading regional segments, including North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa.
The study elaborates on the crucial information pertaining to the regional market share. It simultaneously focuses on the significant details about the growth patterns of each regional market.
Moreover, the report encases an exhaustive geographical study of the market, emphasizing the business growth prospects and market barriers for each of the key market regions.
Read More: https://www.emergenresearch.com/industry-report/biologics-market
Related reports:
Precision Medicine Market: https://www.emergenresearch.com/industry-report/patient-engagement-solutions-market
Precision Medicine Market: https://www.emergenresearch.com/industry-report/nucleic-acid-isolation-and-purification-market
Non-Invasive Prenatal Testing Market: https://www.emergenresearch.com/industry-report/non-invasive-prenatal-testing-market
Medical Radiation Detection, Monitoring, and Safety Market: https://www.emergenresearch.com/industry-report/in-vitro-fertilization-market
Blockchain in Healthcare: Https://www.forbes.com/sites/forbestechcouncil/2021/12/07/four-key-medtech-software-development-trends-for-2022/?sh=23e843f420d
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs